Heart disease remains one of the leading causes of death worldwide, with 50% of cardiac fatalities occurring in individuals without prior risk factors. Despite this alarming reality, there are no widely available, effective tests to prevent these tragedies.
Cardisio, one of Artofin’s recent investments, is addressing this critical gap with its cloud-based AI technology. By replacing outdated diagnostic methods like ECGs, Cardisio offers actionable insights that can save lives and reduce healthcare costs.
Unlike ECGs, which primarily measure heart rhythm, Cardisio’s highly sensitive and affordable test detects arterial and structural heart diseases. The test takes just four minutes to complete and delivers insights that would otherwise require complex and costly procedures.
We are confident in Cardisio’s potential to transform cardiac care. This elegant technology is poised to be widely used and expand into new markets.